Blood Test Detects Advanced CTE in Living Patients, Offering New Diagnostic Path
Researchers at Washington University School of Medicine have identified a blood biomarker, eMTBR-tau243, that can detect advanced chronic traumatic encephalopathy (CTE) in living individuals. While the test cannot diagnose early-stage CTE, it offers a potential tool for monitoring at-risk athletes and initiating drug trials, moving beyond the current requirement for post-mortem brain analysis.
Key points
- A study published in JAMA Neurology found that the protein fragment eMTBR-tau243 is elevated in blood samples from individuals with confirmed CTE.
- The biomarker levels correlate with the severity of the brain disease, allowing for accurate distinction between healthy individuals and those with advanced CTE.
- The test currently fails to reliably identify early-stage CTE, limiting its immediate diagnostic utility for initial detection.
- Researchers suggest the biomarker could be used to monitor athletes with a history of head injuries who test negative for Alzheimer’s disease.
- The finding builds on previous research showing that Alzheimer’s biomarkers can apply to other tauopathies, including CTE.
Background
CTE is a degenerative brain condition caused by repeated head trauma, prevalent in contact sports like American football and rugby. Historically, diagnosis has only been possible after death through brain tissue examination. Recent studies have highlighted the prevalence of CTE among former NFL players, with one analysis of nearly 400 deceased players finding that 93.5% showed evidence of the condition. This development follows other recent biomarker discoveries in related fields, such as blood tests for tinnitus and metabolic conditions, indicating a broader trend toward non-invasive diagnostic tools for neurological and metabolic disorders.
Why it matters
This breakthrough could revolutionize the management of CTE by enabling clinicians to monitor at-risk populations and facilitate clinical trials for potential treatments. It addresses a critical gap in sports medicine, where early detection is currently impossible, and may influence future prevention protocols and legal actions regarding head injuries in professional sports.
What to watch
Large-scale studies are required to validate the biomarker's reliability. If confirmed, the test could be integrated into routine monitoring for athletes with head injury histories, potentially leading to earlier interventions and the development of targeted therapies for CTE.
Want the full story? Read the original reporting
Read on The Guardian